BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Regulatory actions for Nov. 29, 2022
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Regulatory actions for Nov. 29, 2022
Nov. 29, 2022
No Comments
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Ascletis, Biocryst, Biomarin, Blueprint, BMS, Contrafect, Crinetics, CSL, Diamyd, Enlivex, Everest, Exscientia, Gilead, GSK, Junshi, Kintara, Mabwell, Molecure, Opiant, Pacylex, Revive, Roche, Sarepta, Spectrum, Spectrumx, Tenaya.
BioWorld
Briefs
Regulatory
Regulatory actions
Coronavirus